Piper Sandler Reiterates Overweight Rating on BridgeBio Pharma (BBIO)

April 20, 2026 8:32 AM

Piper Sandler analyst Biren Amin reiterated an Overweight rating and $111.00 price target on BridgeBio Pharma (NASDAQ: BBIO).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found